2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1616

Do All Antiphospholipid Antibodies Confer the Same Risk for Major Organ Involvement in Systemic Lupus Erythematosus Patients?
Abstract Number: 2554

Do All Patients Who Achieve Lupus Low Disease Activity State Have Similar Outcomes?
Abstract Number: 604

Do Illness Perceptions and Coping Change over Time in Patients Recently Diagnosed with Axial Spondyloarthritis? A 2-Year Follow-Up Study in the SPACE Cohort
Abstract Number: 2329

Do Myocardial Inflammation and Microvascular Dysfunction in RA Lead to Adverse Changes in Left Ventricular Structure and Function over Time? A Longitudinal Analysis of Participants from Rheumatoid Arthritis: Study of the Myocardium
Abstract Number: 2836

Do Serum Urate-associated Genetic Variants Differentially Contribute to Gout Risk According to Body Mass Index? Analysis of the UK Biobank
Abstract Number: 1230

Do Serum Urate-Associated Genetic Variants Influence Gout Risk in People on Diuretics? Analysis of the UK Biobank
Abstract Number: 854

Do Smoking and Socio-economic Factors Independently Influence Imaging Outcomes in Axial Spondyloarthritis? Five-year Data from the DESIR Cohort
Abstract Number: 311

Documenting Bone Health for Veterans with Rheumatoid Arthritis in an Outpatient Academic Clinic: A Multiphase Quality Improvement Project
Abstract Number: 205

Does a Mandatory Non-medical Switch from Originator to Biosimilar Etanercept Lead to Increase in Healthcare Use and Costs? A Danish Register-based Study of 1620 Patients with Inflammatory Arthritis
Abstract Number: 1846

Does Cartilage Loss Cause Pain in Osteoarthritis?
Abstract Number: 2404

Does Combined Therapy Affects Adherence in Rheumatoid Arthritis?
Abstract Number: 739

Does Digital Thermal Monitoring Correlate to Specific Nailfold Videocapillaroscopy Abnormalities?
Abstract Number: 837

Does Discordance Between Baseline Patient’s and Evaluator’s Global Assessment of Disease Activity Impact Retention and Remission Rates of a First TNF Inhibitor in Patients with Axial Spondyloarthritis? Data from the EuroSpA Research Collaboration Network
Abstract Number: 1088

Does Drug Effectiveness of 2nd and 3rd TNF Inhibitors in Patients with Psoriatic Arthritis Depend on the Reason for Withdrawal from the Previous Treatment? – Results from the EuroSpA Research Collaboration
Abstract Number: 2799

Does Early Anterior Cruciate Ligament Reconstruction Prevent Further Meniscal Damage? Secondary Analysis of a Randomized Controlled Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].